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Interleukin 12 (IL-12) was identified several years ago, but its
potential use in cancer therapy has only been recognised
relatively recently. Animal studies have now shown that IL-
12 has potent anti-tumour and antimetastatic activity, with
less toxicity than that encountered with IL-2. In this
editorial, we review the literature concerning the biology of
IL-12, focusing on the areas of particular relevance to its
possible role in cancer therapy. We propose that an impor-
tant new cytokine has arrived for use in clinical
oncology.
IL-12 (reviewed by Gately, 1993; Brunda, 1994) is a 70-75
kDa glycosylated cytokine which was simultaneously
identified and purified from the supernatant of human B-
lymphoblastoid cell lines by two independent groups and was
initially described on the basis of its actions as 'cytotoxic
lymphocyte maturation factor (CLMF)' (Gately et al., 1986;
Wong et al., 1988; Stern et al., 1990) and 'natural killer cell
stimulatory factor (NKSF)' (Kobayashi et al., 1989). It has
an atypical structure for a cytokine, being heterodimeric and
consisting of a 35 kDa (p35) subunit and a 40 kDa (p40)
subunit linked by a disulphide bond. A mixture of soluble
recombinant subunits also has biological activity but only at
concentrations several orders of magnitude greater than that
of the covalently linked heterodimer (Trinchieri, 1993). The
genes for both the p35 and p40 subunits have been cloned
(Gubler et al., 1991; Wolf et al., 1991) and mapped in
humans to chromosomes 3pl2-3ql3.2 and 5q31-q33 respec-
tively (Sieburth et al., 1992). The predicted amino acid
sequences of the human p35 and p40 IL-12 subunits show
60% and 70% identity with the murine sequences and consist
of 20% and 10% carbohydrate respectively (Podlaski et al.,
1992; Schoenhaut et al., 1992). Bioactivity studies, however,
show species specificity, with human IL-12 exhibiting mini-
mal activity in the murine system but with murine IL-12
being active in human systems. The use of interspecies p35/
p40 hybrids suggests that this is determined by the p35
subunits (Schoenhaut et al., 1992). However, as antibodies
against the p40 subunit can neutralise IL-12 bioactivity, both
subunits may be involved in receptor binding (Chizzonite et
al., 1991; D'Andrea et al., 1992), either directly or possibly
through one subunit influencing the conformational state of
the other.
The main cellular sources of IL-12 are monocytes/macro-
phages, which secrete IL-12 constitutively and particularly
following stimulation with bacterially derived products, and
B cells and B-lymphoblastoid cell lines (D'Andrea et al.,
1992). Incubation of peripheral blood mononuclear cells
(PBMCs) with Staphylococcus aureus Cowan I strain or lipo-
polysaccharide (LPS) increases production of IL-12 but a
range of cytokines, including IL-la, IL-1p, IL-2, IL-4, IL-6
and tumour necrosis factor alpha (TNF-a), do not elicit
increased production (D'Andrea et al., 1992), and IL-10 has
been reported to inhibit synthesis of IL-12 by PBMCs
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(D'Andrea et al., 1992; Kubin et al., 1994). Discordant pro-
duction of the subunits has been demonstrated, indicating
independent regulation, with excess uncomplexed p40 being
produced by human PBMCs and B-lymphoblastoid cell lines,
although production of free p35 has not been observed (Stem
et al., 1990; Wolf et al., 1991; D'Andrea et al., 1992). A
range of solid tumour-derived, T-cell and myeloid leukaemic
cell lines have been found not to secrete IL-12, although
many of these cell lines contain mRNA transcripts of the p35
gene alone (D'Andrea et al., 1992). Similarly, in the murine
system, p40 mRNA has been found to be restricted to lym-
phoid tissues, whereas p35 mRNA is detected in both lym-
phoid and non-lymphoid (lung and brain) tissues (Schoen-
haut et al., 1992). However, mRNA for both subunits has
been found in two murine thymic epithelial lines and a
thymic fibroblastoid clone (Godfrey et al., 1994), although it
is not known whether these cell types secrete mature IL-12
protein. It is unclear whether the individual IL-12 subunits
can exert as yet unidentified biological effects, but the murine
p40 subunit is able to inhibit several biological activities of
the IL-12 heterodimer (Mattner et al., 1993). This may be
analogous to the IL-1 family, in that IL-la and -P can bind
to and elicit responses in target cells, but the third member,
the IL-1 receptor antagonist, can bind to the receptor but
does not induce a response and can competitively inhibit
IL-la or -1. In effect, the excess of free p40 produced by
some cells may serve to regulate the biological activity of
IL-12.
A high-affinity 110-135 kDa receptor with a Kd of
100-600pM has been found on activated human T cells and
NK cells but not on B cells, resting PBMCs or several cell
lines, including those of T, NK, B, myelomonocytic, epithe-
lial and fibroblast lineage (Chizzonite et al., 1992; Desai et
al., 1992). Subsequently, a more detailed analysis has
identified three binding sites on phytohaemagglutinin (PHA)
activated PBMCs with apparent Kd of 5-20pM and 2-6 nM
(Chua et al., 1994). The extensive homology between the p40
subunit and the extracellular domain of the IL-6 receptor,
together with the more distant relationship between the p35
subunit and IL-6 itself (Gearing and Cosman, 1991; Merberg
et al., 1992), has provoked speculation that the IL-12
heterodimer may have evolved from a cytokine/soluble recep-
tor complex, such as occurs with IL-6, which then interacts
with a cell-bound receptor analogous to gpl30 and induces
biological activity. This has been given further support by the
recent cloning of the cDNA encoding a human IL-12 recep-
tor subunit of approximately 100 kDa which structurally is a
member of the haematopoietin receptor family and most
closely related to gpl3O (Chua et al., 1994). However, unlike
the IL-6/soluble IL-6R-induced dimerisation of gpl3O and
subsequent signal transduction, the oligomerisation of the
IL-12R subunit is not dependent on ligand binding and IL-12
only binds dimeric or oligomeric forms of the subunit. Addi-
tionally, whereas gp130 expression is widespread, constitutive
and converts the IL-6/IL-6R interaction to one of high
affinity, the IL-12R subunit is restricted, highly inducible by
mitogens or IL-2 and is thought to represent the low-affinitylnterbukin 12: a now clinical player
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IL-12 binding site (Kd 2-5 nM) requiring an additional sub-
unit to generate a high affinity IL-12R complex. This may be
the receptor-associated protein of 85 kDa previously des-
cribed (Chizzonite et al., 1992).
It is now recognised that IL-12 has several biological
actions including playing a pivotal role in the initiation of
cell-mediated immunity via regulation of THI and TH2 sub-
sets (Romagnani, 1992; Germann et al., 1993; Hsieh et al.,
1993; Macatonia et al., 1993; Manetti et al., 1993; Trinchieri,
1993; Wu et al., 1993; McKnight et al., 1994; Romani et al.,
1994; Schmitt et al., 1994; Yanagida et al., 1994). In both
murine and human systems, it appears that IL-12 is an
essential factor for TH1 generation, with antigenic stimulation
in the presence of blocking antibodies to IL-12 preventing
the generation of THI cells. This may at least in part be
independent of interferon-', although studies with neutralis-
ing antibodies have produced conflicting results, but may
require NK cells (Macatonia et al., 1993; Manetti et al.,
1993; Wu et al., 1993; McKnight et al., 1994). Conversely,
IL-4 induces the generation of TH2 cells. Thus, the critical
balance ofcytokines and particularly IL-4 and IL-12 is essen-
tial for determining the THI and TH2 response. Appropriate
negative and positive feedback mechanisms exist, with the
THI-derived interferon-y further increasing the monocytic
production of IL-12 and decreasing IL-10 production, where-
as the TH2 cell products, IL4 and IL-10, inhibit production
of IL-12 (Trinchieri, 1993). Activated but not resting T and
NK cells, whether isolated from peripheral blood lympho-
cytes (PBLs), T-cell lines or tumour-infiltrating lymphocytes
(TILs), proliferate in response to IL-12 via a mechanism
which is in most cases IL-2-independent (Stern et al., 1990;
Gately et al., 1991; Wolf et al., 1991; Bertagnolli et al., 1992;
Naume et al., 1992; Perussia et al., 1992; Andrews et al.,
1993) although additive, synergistic or inhibitory effects of
IL-2 have been reported. However, IL-12 has also been
reported to inhibit the proliferative response of NK cells,
CD8+ cells and a T-cell line to high-dose IL-2 (Perussia et
al., 1992; Robertson et al., 1992; Mehrotra et al., 1993).
Synergy of IL-12 with the B7/CD28-mediated co-stimulation
of proliferation and cytokine production of murine and
human T cells has also been shown to occur (Kubin et al.,
1994; Murphy et al., 1994), with effective concentrations of
IL-12 being lower and inducing greater responses than those
of IL-2 (Kubin et al., 1994). IL-12 is not, however, an
effective stimulus for anergic T cells (Quill et al., 1994).
Whether the IL-12-facilitated induction of MHC-restricted
cytotoxic T-lymphocyte activity seen in vitro is IL-2 depen-
dent is the subject of dispute (Gately et al., 1992; Mehrotra
et al., 1993; Bloom and Horvath, 1994), presumably because
of factors such as the nature of the stimulus and the cell
populations used. An increase in production of granule pro-
teins such as perforin has been associated with the IL-12-
enhanced MHC-restricted and non-restricted cytotoxicity
(Cesano et al., 1993; Chehimi et al., 1993; Salcedo et al.,
1993; Aste-Amezaga et al., 1994; Bloom and Horvath, 1994;
Bonnema et al., 1994).
IL-12 markedly stimulates production of interferon-y from
resting or activated PBLs and T and NK cells (Kobayashi et
al., 1989; Chan et al., 1991; Wolf et al., 1991; Naume et al.,
1993; Wu et al., 1993), acting synergistically with IL-2,
although resting cells also require accessory cells. The action
of IL-12 in enhancing the cytolytic activity of NK cells and
induction of LAK activity (Kobayashi et al., 1989; Stern et
al., 1990; Gubler et al., 1991; Wolf et al., 1991; Gately et al.,
1992; Naume et al., 1992; Robertson et al., 1992; Chehimi et
al., 1993) is not thought to be mediated by IL-2 or inter-
feron-y. However, production of endogenous TNF-a has
been implicated in the IL-12-mediated generation oflympho-
kine-activated killer cell (LAK) activity (Gately et al., 1992;
Naume et al., 1992), but whether it is involved in the
augmentation of NK cytotoxic activity in short-term cultures
may be dependent on whether mature or immature NK cells
are used (Chehimi et al., 1993; Jewett and Bonavida, 1994).
IL-12 has been reported to both inhibit and act synergis-
tically with IL-2-induced LAK activity depending on the
experimental conditions (Gately et al., 1992; Zeh et al., 1993)
and, indeed, endogenous IL-12 may be a partial mediator of
the IL-2 response, with antibodies to IL-12 producing a 50%
inhibition of IL-2-induced interferon-y production by PBLs
in vitro (D'Andrea et al., 1992). Interestingly, in view of
IL-10's ability to inhibit IL-12 synthesis (D'Andrea et al.,
1993), following IL-12 injection in mice, a decrease in splenic
IL-3 and IL-4 production was noted together with an in-
crease in IL-10 production (Morris et al., 1994), possibly
indicating a negative feedback mechanism. Other biological
actions of IL-12 include the up-regulation of HLA-DR, the
adhesion molecules ICAM-1, and LFA-1 and receptors for
the cytokines IL-2, IL-12, IL-4 and TNF on NK cells
(Naume et al., 1992, 1993; Robertson et al., 1992; Rabino-
wich et al., 1993; Jewett and Bonavida, 1994), the inhibition
of IgE production (Kiniwa et al., 1992; Morris et al., 1994),
and actions as a growth modulator for murine and human
haemopoietic stem cells (Jacobsen et al., 1993; Ploemacher et
al., 1993a,b; Bellone and Trinchieri, 1994).
Clearly, the above actions of IL-12 indicate its potential
usefulness as an anti-tumour agent, and this is borne out by
recent experimental work. In vitro IL-12 has been shown to
augment significantly the NK activity of human PBMCs
against a variety of tumour-derived cell lines, including colon
and neuroblastoma (Lieberman et al., 1991; Rossi et al.,
1994) and to correct the defect of NK activity of PBMCs
seen in patients with various solid tumours (Soiffer et al.,
1993; Kusher et al., 1994). In those patients receiving IL-2,
co-culture of PBMCs with IL-12 produced a dramatic in-
crease in cytolytic activity against NK-sensitive and NK-
resistant tumour targets (Soiffer et al., 1993). The cytolytic
activity of TILs against autologous tumours including mela-
noma, breast and ovary (Andrews et al., 1993; Zeh et al.,
1993) is also enhanced by IL-12.
Early animal studies have now shown that IL-12 admini-
stered either systemically, directly into the tumour or locally
by fibroblasts genetically engineered to produce IL-12 has
potent anti-tumour and antimetastatic activity in a number
of tumour models, including carcinomas, sarcomas, melano-
mas and lymphomas (Brunda et al., 1993; O'Toole et al.,
1993; Tahara et al., 1994; Mayor et al., 1994; Nastala et al.,
1994; Stern et al., 1994). Most importantly, IL-12 was not
only able to inhibit growth of new tumours but also caused
regression of existing extensive tumours. Whether IL-12 is
having any direct effects on the tumours is not clear,
although in vitro it has no effect on the proliferation of
several murine tumour cell lines (Brunda et al., 1993;
O'Toole et al., 1993; Mayor et al., 1994). Both increased NK
lytic activity and specific allogeneic cytotoxic T-lymphocyte
(CTL) responses have been seen in normal mice injected with
IL-12 (Gately et al., 1994), although NK activity was low
and declined within 2 days. As IL-12 retains its anti-tumour
activity in mice depleted of NK cells but not in nude mice, it
has been suggested that activation of T cells rather than of
NK cells is the predominant mechanism of its anti-tumour
activity (Brunda et al., 1993). This is supported by the reduc-
tion of efficacy of IL-12 with depletion of CD8+ cells but not
with CD4+ cells, the latter finding being somewhat surprising
given the actions of IL-12 on CD4+ THI cells (Brunda et al.,
1993). However, a further study has found that the elimina-
tion of both CD4+ and CD8+ subsets is necessary before the
effect of IL-12 is lost (Nastala et al., 1994). In addition, other
studies have found that the anti-tumour effect is present in
severe combined immunodeficient (SCID) mice which lack B
or T cells, implicating NK cells (O'Toole et al., 1993). Co-
injection of NK cells with IL-12 produced no appreciable
anti-tumour effect on human melanoma xenografts in SCID
mice, but the co-injection of IL-12 with IL-2 and NK cells
significantly increased the anti-tumour effect of IL-2 and NK
cells alone (Hill et al., 1994).
The extent to which the anti-tumour activity of IL-12 is
mediated by the secondary induction of interferon-y is not
clear, but dramatically increased serum levels of interferon-y
are seen in mice following IL-12 administration (Gately et
al., 1994; Hendrzak et al., 1994; Nastala et al., 1994) with
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antibodies to interferon-y nearly completely abrogating the
anti-tumour, and partially reducing the antimetastatic, effects
of IL-12 (Hendrzak et al., 1994; Nastala et al., 1994).
Administration of interferon-?i alone, however, fails to pro-
duce the anti-tumour effects, suggesting that, although pro-
duction of interferon-'y is essential for the anti-tumour action
of IL-12, other cytokine cascades/actions of IL-12 are also
required. Only low levels of TNF-a are found following
IL-12 administration and antibodies to TNF-x have no effect
on the anti-tumour activity of IL-12 (Nastala et al., 1994).
Initial reports indicate that, in contrast to IL-2, little toxicity
has so far been associated with administration of IL-12 to
mice at effective doses (1 ,ig day-') (Brunda et al., 1993;
Gately et al., 1994; Nastala et al., 1994; Stern et al.,
1994).
IL-12 is clearly a cytokine which plays a central role in
directing the immune response. Its involvement in cell-
mediated immunity, both as an initiator and as a facilitator,
makes it a promising agent for immunotherapy. In addition,
its interactions with other cytokines in mediating this res-
ponse suggests that it could be used in combination with
already established therapies and additionally may be amen-
able to gene therapy strategies. Preclinical studies have
clearly shown its potential in animal studies, and a plethora
of clinical trials will undoubtedly follow to establish if the
immunotherapeutic potential demonstrated in animal studies
is realised in human malignancies.
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